Ensysce Biosciences Closes $2M Convertible Financing with $0.55 Conversion Price
Ensysce Biosciences closed a $2 million tranche of its November 2025 financing commitment, extending up to $20 million over 24 months to support its flagship analgesic programs. The tranche carries a $0.55 conversion price and two sets of 100% warrants exercisable over 18 months and five years.
1. Financing Closure Details
Ensysce Biosciences has drawn down a $2 million tranche under its November 2025 agreement, which allows for up to $20 million in funding over 24 months. This draw reinforces the company’s liquidity position as it advances its clinical-stage analgesic candidates.
2. Conversion and Warrant Terms
The convertible preferred stock tranche features a fixed conversion price of $0.55 per share with an alternate conversion based on average common stock prices. Investors receive 100% warrant coverage exercisable at the same $0.55 price, split into an 18-month term and a separate five-year term, each subject to standard adjustments.
3. Use of Proceeds and Strategic Impact
Proceeds will underwrite Ensysce’s flagship analgesic programs leveraging its TAAP and MPAR platforms and fund general corporate initiatives. Company leadership highlights continued investor confidence and federal grant support as key enablers for sustaining development of overdose-resistant pain therapies.